Oligonucleotide compositions and methods thereof
Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
1. An oligonucleotide having the structure of:
mG * SmUmGmCmA * SC * SA * SC * SA * SG * ST * SA * SG * RA * ST * SmGmAmGmG * SmG (SEQ ID NO: 1467), or a pharmaceutically acceptable salt thereof, wherein:
*S represents a Sp phosphorothioate;
*R represents a Rp phosphorothioate; and
m represents a 2′-OMe modification to a nucleoside.
2. The oligonucleotide of claim 1 , wherein the oligonucleotide is in a salt form.
3. The oligonucleotide of claim 1 , wherein the salt is a sodium salt.
4. An oligonucleotide, wherein the oligonucleotide is a sodium salt of:
mG * SmUmGmCmA * SC * SA * SC * SA * SG * ST * SA * SG * RA * ST * SmGmAmGmG * SmG (SEQ ID NO: 1467), wherein:
*S represents a Sp phosphorothioate;
*R represents a Rp phosphorothioate;
m represents a 2′-OMe modification to a nucleoside; and
the number of sodium ions in the sodium salt equals the total number of phosphorothioate and phosphate linkages in the oligonucleotide.
5. A chirally controlled composition of an oligonucleotide having the structure of:
mG * SmUmGmCmA * SC * SA * SC * SA * SG * ST * SA * SG * RA * ST * SmGmAmGmG * SmG (SEQ ID NO: 1467), or a pharmaceutically acceptable salt thereof, wherein:
*S represents a Sp phosphorothioate;
*R represents a Rp phosphorothioate; and
m represents a 2′-OMe modification to a nucleoside,
wherein the composition is enriched, relative to a substantially racemic preparation of the oligonucleotide for the oligonucleotide.
6. The composition of claim 5 , wherein the oligonucleotide is in a salt form.
7. The composition of claim 5 , wherein the oligonucleotide is a sodium salt.
8. The composition of claim 7 , wherein the number of sodium ions in the sodium salt equals the total number of phosphorothioate and phosphate linkages in the oligonucleotide.
9. A pharmaceutical composition, comprising a therapeutically effective amount of an oligonucleotide and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers, wherein the oligonucleotide has the structure of:
mG * SmUmGmCmA * SC * SA * SC * SA * SG * ST * SA * SG * RA * ST * SmGmAmGmG * SmG (SEQ ID NO: 1467), or a pharmaceutically acceptable salt thereof, wherein:
*S represents a Sp phosphorothioate;
*R represents a Rp phosphorothioate; and
m represents a 2′-OMe modification to a nucleoside.
10. The composition of claim 9 , wherein the oligonucleotide is in a salt form.
11. The composition of claim 9 , wherein the oligonucleotide is a sodium salt.
12. The composition of claim 9 , wherein the number of sodium ions in the sodium salt equals the total number of phosphorothioate and phosphate linkages in the oligonucleotide.